JOHNSON & JOHNSON is 167.4x more valuable than NewAmsterdam Pharma Company N.V. by market capitalization ($573.98 B vs $3.43 B). Every figure below comes from audited SEC filings and refreshed market data.
| Metric | NAMS | JNJ |
|---|---|---|
| Market cap | $3.43 B | $573.98 B |
| US-listed rank | #1703 | #20 |
| Revenue (latest FY) | $22.50M | $94.19B |
| Net income (latest FY) | -$203.00M | $26.80B |
| Net margin | -902.1% | 28.5% |
| P/E (trailing FY) | - | 21.4 |
| SEC filings | 386 | 984 |
JOHNSON & JOHNSON is 167.4x more valuable than NewAmsterdam Pharma Company N.V. by market capitalization ($573.98 B vs $3.43 B).
In their latest fiscal years, NewAmsterdam Pharma Company N.V. reported $22.50M in revenue while JOHNSON & JOHNSON reported $94.19B.
Full pages: NewAmsterdam Pharma Company N.V. and JOHNSON & JOHNSON, or browse the full rankings.